-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to preliminary results from a Phase III clinical trial reported in the New England Journal of Medicine, the COVID-19 vaccine mRNA-1273 is 94.1% effective in preventing COVID-19.
the vaccine has also shown the efficacy of preventing severe COVID-19.
found no safety risks and no vaccine-related evidence of respiratory disease (VAERD).
vaccine was developed by Modelna, a Cambridge, Massachusetts-based biotech company, and the National Institutes of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health.
December 18, 2020, the FDA issued an emergency use authorization to allow the vaccine to be used in U.S. adults to prevent COVID-19.
trial began on July 27, 2020, recruiting 30,420 adult volunteers at clinical research centers in the United States.
volunteers were randomly assigned 1:1 to receive a research vaccine or placebo.
The average age of volunteers was 51, 47 per cent were women, 25 per cent were women aged 65 or over, 17 per cent were women under 65, about 79 per cent were white, 10 per cent were black or African-American, 5 per cent were Asian, 0.8 per cent were Amerindians or Alaska Natives, 0.2 per cent were Native Hawaiians or other Pacific Islanders, and 2 per cent were multiracial.
。
